A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer

PURPOSE: To determine the maximum tolerated dose (MTD), characterize the principal toxicities, and assess the pharmacokinetics of EKB-569, an oral selective irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with capecitabine in patients with advanced colo...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Laheru, Dan, Croghan, Gary, Bukowski, Ronald, Rudek, Michelle, Messersmith, Wells, Erlichman, Charles, Pelley, Robert, Jimeno, Antonio, Donehower, Ross, Boni, Joseph, Abbas, Richat, Martins, Patricia, Zacharchuk, Charles, Hidalgo, Manuel
Format: Artigo
Sprog:Inglês
Udgivet: 2008
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3086427/
https://ncbi.nlm.nih.gov/pubmed/18765554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0433
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker